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ABSTRACT
Neural cells undergo glutamate-induced apoptosis
in ischaemic brain tissue, in which prostate apopto-
sis response-4 gene (Par-4) is involved. Human-
bone mesenchymal stem cells can be utilized as
an effective therapy for ischemic brain injury. In
this study, we found that glutamate could induce
apoptosis in human-bone mesenchymal stem cells,
accompanied by increased expression of Par-4 gene
and Smac release from mitochondria. Repressing
Par-4 expression attenuated the glutamate-induced
apoptosis. Both Par-4 protein and E2F1 protein could
bind to E2F1-binding BS3 site on Smac promoter and
participated in the formation of a proteins-DNA com-
plex. Moreover, in the complex, E2F1, not Par-4,w a s
found to be directly bound to the Smac promoter,
suggesting that Par-4 exerted indirectly its transcrip-
tional control on the Smac gene though interacting
with E2F1. Expression of full-length Par-4 in human-
bone mesenchymal cells resulted in increased activ-
ity of the Smac promoter. In addition, the indirect
transcripional regulation of Par-4 on Smac depended
on its COOH terminus-mediated interaction between
Par-4 and E2F1. We conclude that the formation of
proteins–DNA complex, containing Par-4 protein,
E2F1 protein and the Smac promoter, contributes
to the pro-apoptotic effect on glutamate-treated
human-bone mesenchymal stem cells.
INTRODUCTION
As a major contributor to death and disability, ischaemic
brain injury does not only aﬀect adults (1,2), it is also an
important cause of mortality and severe neurodevelop-
mental morbidity in children, such as cerebral palsy,
mental retardation, epilepsy and learning disability (3).
Human-bone mesenchymal stem cells (hBMSCs) are self-
renewing multipotent cells, which can be utilized as an
eﬀective therapy for ischemic brain injury. However,
although considerable studies have been devoted to inves-
tigating the therapeutic eﬃcacy of hBMSCs transplanta-
tion in ischemic brain, rather less attention has been paid
to the biochemical regulation of the stem cell itself in
a pro-apoptotic microenvironment of ischaemic brain
tissue. Thus, it is of paramount importance to investigate
the events and factors that predispose hBMSCs to
undergo apoptosis in ischaemia tissue.
Glutamate, an excitatory amino acid, binds to postsyn-
aptically located glutamate receptors that regulate calcium
channels in ischaemic brain tissue. The resulting calcium
inﬂux activates proteases, lipases and endonucleases,
which in turn destroy the cellular skeleton, ﬁnally leading
to cells necrosis or switch on apoptosis (4). The implanted
stem cells will suﬀer from the impairment of excitotoxic
glutamate as well in such a microenvironment. Hence, for
alleviating suﬀering and improving survival of implanted
cells in ischaemic brain tissue, it is important to determine
how hBMSCs respond to glutamate.
The prostate apoptosis response factor-4 (Par-4) gene
was originally identiﬁed by diﬀerential screening for
up-regulated genes in apoptotic prostate cell (5).
Subsequently, Par-4 was found to possess potent apopto-
tic activity in various cellular systems. In the past few
years, several studies have investigated the role of Par-4
in cell apoptosis and found that Par-4 had been attributed
a crucial function to its COOH terminus domain (6,8).
One of the most noticeable structural features of Par-4
COOH terminus was the leucine zipper repeats, a putative
death domain, which was found in several other proteins
involved in apoptosis, suggesting the importance of this
region in Par-4 function (7,9). However, despite the
advances made in understanding the role of Par-4 in apo-
ptosis, little was known about whether Par-4 is involved in
the response of glutamate-treated hBMSCs.
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pase), also known as DIABLO (direct IAP-binding protein
with low pI), is a pro-apoptotic protein and is normally
compartmentalized and stored in mitochondria upon
receiving apoptotic stimuli; Smac is released into cytosol,
where it binds to IAPs, and active caspases either by era-
dicating the binding capability of IAPs to caspases or
enhancing the proteosome-mediated degradation of IAPs
(10,11). In addition, E2F1, a member of E2F transcription
factor family, can bind to the Smac promoter and tran-
scriptionlly upregulate Smac expression, which results into
the mitochondria-mediated apoptosis (12). However, it
remains unclear whether Smac plays a role in glutamate-
induced hBMSCs apoptosis.
In this study, we demonstrate for the ﬁrst time that
excitotoxic glutamate can induce hBMSCs apoptosis,
accompanied by increased expression of Par-4 and Smac
release from mitochondria. Our results indicate that the
glutamate-induced pro-apoptotic eﬀect on hBMSCs is
partially due to the formation of multimolecular complex
of Par-4, E2F1 and Smac promoter. Our results show that
Par-4 can transcriptionally modulate Smac expression
through the indirect interaction between Par-4 and Smac
promoter. The association of Par-4 with E2F1 which
depended on the COOH terminus of Par-4, enhances the
capability of E2F1 binding to Smac promoter. In conclu-
sion, our ﬁndings provided the detailed molecular
mechanisms responsible for glutamate-induced apoptosis
in hBMSCs.
MATERIALS AND METHODS
Reagents andantibodies
Par-4 rabbit polyclonal antibody, E2F1 rabbit polyclonal
antibody and FITC conjugated anti-rabbit IgG secondary
antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The majority of
reagents used for this study, including glutamate and
DAPI, were obtained from Sigma–Aldrich (St Louis,
MO, USA). Anti-CD105 (endoglin), -CD73, -CD106
(VCAM-1), -CD44,-CD90, -CD29, -CD45, -CD14,
-CD34, -CD80, -CD86 antibodies, were purchased from
BD Biosciences (La Jolla, CA, USA). pGEMT-easy
vector, Gel Shift Assay kit, pGL3 Luciferase Reporter
Vector were obtained from Promega (Madison, WI,
USA). Advantage 2 DNA polymerase and pcDNA3.1/
myc-his vector were obtained from BD Biosciences (La
Jolla, CA, USA). Restriction endonucleases were pur-
chased from New England BioLab (Beverly, MA, USA).
Endo-free Plasmid Maxi kit was obtained from Qiagen
(Hilden, Germany). Lipofectamine 2000 reagent was
obtained from Invitrogen (Carlsbad, CA, USA). Nuclear
Protein Extraction kit was purchased from Active Motif
(Carlsbad, CA, USA).
Cellculture andhBMSCs phenotypeanalysis
Culture and characterization of hBMSCs were performed
as described previously (13). Brieﬂy, bone marrow cells
were obtained from 5ml aspirates from the iliac crest of
normal donors after informed consents were given.
Cells were plated at a density of 5 10
6 per 25cm
2 ﬂask
in 5ml Dulbecco’s modiﬁed Eagle’s medium (DMEM) sup-
plemented with 100mg/ml penicillin, 100mg/ml streptomy-
cin and 10% fetal calf serum, incubated at 378Ci na
humidiﬁed atmosphere containing 5% CO2. After 72h,
non-adherent cells were discarded and adherent cells were
washed gently with DMEM medium and cultured for
 21 days. The culture medium was replaced with fresh
complete medium twice a week. Upon reaching near con-
ﬂuence, cells were detached with a solution of 0.25% tryp-
sin and 100mMol/l EDTA for 2–3min at 378Ca n dp l a t e d
at 1000cells/cm
2 with medium replacement twice a week.
Cells used in our experiments were the ﬁfth or sixth passage
of cultivation. hBMSCs were immunophenotyped by ﬂuor-
escence-activated cell sorting (FACS). Cells were detached
with trypsin-EDTA, washed in PBS, and immediately
stained with the following labelled antibodies: CD105-
FITC, CD73-FITC, CD44-FITC, CD90-FITC, CD147-
FITC, HLA Class I-FITC, CD29-FITC, CD34-PE,
CD45-PE, CD14-PE, CD11b-PE and HLA-DR-PE and
then analysed using a ﬂow cytometry.
Fluorescence-activated cell sorter analysis
hBMSCs were harvested in the presence or absence of
1—100mM glutamate for 6, 12 or 24h. Cells were col-
lected by trypsinization and washed in PBS. After incuba-
tion with 5ml of Annexin V-FITC and 10ml of propidium
iodide (PI, 50mg/ml) at room temperature for 15min in
the dark, cells were analysed by ﬂow cytometry. The per-
centages of apoptosis in the cells were calculated by data
from FACS analysis and the result is presented in the bar
graph relative to the apoptotic cell rate in hBMSCs with-
out treatment of glutamate.
DNA fragmentationassay
DNA fragmentation was assessed using a soluble DNA
preparation as previously described (14). hBMSCs were
harvested in the presence or absence of 100mM glutamate
for 24h. Then cells were lysed in 10mM Tris–HCl (pH
7.5) containing 10mM EDTA and 0.2% Triton X-100.
The lysate was centrifuged at 12000g for 10min. The
supernatant was treated with proteinase K (0.3mg/ml)
and RNase A (0.3mg/ml) and then extracted in the pre-
sence of 300mM NaAc. The DNA was precipitated with
isopropanol and dissolved in 10mM Tris–HCl (pH 8.0)
containing 100mM EDTA. The DNA was electrophoresed
in 1.5% agarose gel in Tris borate-EDTA buﬀer. The
DNA bands were then imaged by ethidium bromide stain-
ing and photographed.
Subcellular fractionation
Cells were washed once in PBS and harvested in isotonic
buﬀer (250mM sucrose, 1mM EDTA and 10mM
HEPES, pH 7.4) supplemented with 0.25mM phenyl-
methylsulfonyl ﬂuoride, 10mg/ml leupeptin and 10mg/ml
aprotinin. After a brief sonication, samples were trans-
ferred to 1.5-ml tubes and centrifuged at 900g for 10min
at 48C to eliminate nuclei and unbroken cells. Supernatant
was then centrifuged at 9500g for 15min at 48C to obtain
the heavy membrane pellet enriched for mitochondria,
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Western blotting analysis
Cells were collected by trypsinization and washed in PBS.
Then cell pellets were lysed in 1% Nonidet P-40 lysis
buﬀer (150mM NaCl, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% SDS, 50mM Tris, pH 8.0), to which
2mM phenylmethylsulfonyl ﬂuoride, 3.3mg/ml leupeptin
and 5mg/ml pepstatin were added fresh before use. Fifty
micrograms of proteins was loaded on precast SDS/Tris/
glycine gels, and after electrophoresis, proteins were trans-
ferred to nitrocellulose membranes, which were blocked in
5% non-fat dry milk and blotted with the appropriate
primary antibody. Membranes were then incubated with
the appropriate secondary antibody linked to horseradish
peroxidase and developed using the ECL kit according to
the manufacturers’ protocols. Smac levels were repre-
sented as ratios between the levels in mitochondria
versus cytosol.
Small interfering RNA-based (siRNA) experiments
A small interfering RNA-based (siRNA) strategy was
employed to silence endogenous human Par-4 in
hBMSCs. Par-4 and scrambled siRNAs were generated
using the procedure of siSTRIKE
TM U6 Hairpin
Cloning Systems (Promega, Madison, WI). The four
siRNAs had the following sense strand sequences:
Par-4-siRNA-1:
50-ACCGTCACAGCCGTTTGAATATATTTCAAGA
GAATATATTCAAACGGCTGTGACTTTTTC-30.
Par-4-siRNA-2:
50-ACCGGAAACGAGAAGATGCAATTATTCAAG
AGATAATTGCATCTTCTCGTTTCCTTTTTC-30.
Par-4-siRNA-3:
50-ACCGTGAGACTGATGCAAGATAAATTCAAG
AGATTTATCTTGCATCAGTCTCACTTTTTC-30.
Par-4-siRNA-4:
50-ACCGAACAGTTTCAGGCAGATATATTCAAG
AGATATATCTGCCTGAAACTGTTCTTTTTC-30.
The target sequences for the Par-4 gene are underlined.
Sense and antisense strands were annealed and ligated into
linearized psiSTRIKE Vector following the manufac-
turer’s directions. Sequence analysis of transformed ran-
domly picked clones was used to conﬁrm sequence
integrity of Par-4 siRNA plasmids. Cells were transfected
with siRNA or the indicated constructs using
Lipofectamine 2000 in Opti-MEM I for 24h, and then
the medium was changed back to growth medium for
additional incubation. Green ﬂuorescent protein
phMGFP vector was cotransfected to determine transfec-
tion eﬃciency with ﬂow cytometry assay. Forty-eight
hours after transfection, total RNA was prepared and
used to perform real time quantitative PCR analysis.
The level of target RNA suppression in transfected cells
were determined by normalizing for transfection eﬃ-
ciency. Small interfering RNA-based experiment for
Smac and E2F1 were similarly performed.
RT–PCR analysis
Cells were harvested, and total RNA extraction was per-
formed. RNA purity (A260/A280 >1.6) was checked by a
spectrophotometer (GeneQuant, Type II; Pharmacia,
Uppsala, Sweden), and RNA integrity was conﬁrmed by
visualization of 28 and 18s bands (2:1) on 1% agarose gel.
Subsequently, 1mg of RNA was reverse transcribed using
the Moloney-murine leukaemia virus reverse transcription
system. The beta-actin was used as internal controls. PCR
reactions were performed in a 50ml mixture containing
10 PCR buﬀer, MgCl2, dNTP, and Taq DNA polymer-
ase. Ampliﬁcation protocols for Smac and beta-actin con-
sisted of 30 repetitive cycles of pre-denaturing at 958C for
4min, denaturing at 948C for 30s and annealing at 608C
for 60s. Ampliﬁed cDNA was separated by 2% agarose
gel electrophoresis and visualized with ethidium bromide.
Semiquantitative analysis was performed using UVP-gel
densitometry (San Gabriel, CA, USA). Arbitrary
unit=(ASmac/Abeta-actin) 100%.
Realtime quantitative PCR
Total RNA extraction was performed using TriZol
reagent followed by chloroform-isopropanol extraction
and ethanol precipitation. Subsequently, duplicate sam-
ples of 1ml of each cDNA were used as a template. Real
time quantitative PCR was performed using the ABI
PRISM 7700 sequence detection system (PE Applied
Biosystems, Wellesley, MA, USA). We used primers and
a probe generated by the program Primer Premier. Par-4
primers were F (forward) 5-GCCGCAGAGTGCT
TAGATGAG-3 and Par-4R (reverse) 5-GCAGATA
GGAACTGCCTGGATC-3 (fragment length, 136bp).
TaqMan probe (FAM-labelled 5-ACGAAGATGAT
GAAGCAGGGCAGAAAGAG-3) was added to the
PCR mixture to a ﬁnal concentration of 200nM.
GAPDH primers were F (forward) 5-GAAGGTGAA
GGTCGGAGTC-3 and GAPDH R (reverse) 5-GA
AGATGGTGATGGGATTC-3 and GAPDH TaqMan
probe ﬂuorescence labeled 5F 5-CAAGCTTCCCGTTC
TCAGCC-3 were used as internal controls. Ampliﬁcation
conditions were as follows: 508C for 2min, 958C for
10min and then 40 cycles at 958C for 15s and 608C for
60s. GAPDH was co-ampliﬁed with Par-4. Average
threshold cycle (Ct) values from the triplicate PCR reac-
tions for Par-4 were normalized against the average Ct
values for GAPDH from the same cDNA sample. The
fold change of Par-4 transcript levels between Par-4-
siRNA-1,2,3,4 and the control equals 2
 Ct, where
Ct=Ct Par-4 Ct GAPDH, and Ct=Ctcontrol 
CtPar-4-siRNA-1,2,3,4. Real time quantitative PCR for
Smac was similarly performed.
Construction of expression plasmids and transient
transfection
To construct and clone the eukaryotic expression vector of
human Par-4, full-length cDNA of Par-4 was ampliﬁed by
Rt–PCR from human neuroblastoma cell line SK-N-SH
(Shanghai Institute of Cell Biology, Chinese Academy
of Science, Shanghai, Peoples’ Republic of China).
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plasmid pGEM-T and transformed into Escherichia coli
JM109. Positive clones were ampliﬁed, screened and iden-
tiﬁed by sequencing. Then Par-4 cDNA was subcloned
into pcDNA3.1 vector between the restriction enzyme
sites HindIII and XhoI to generate the pcDNA3.1-Par-4
construct. For construction of pcDNA3.1-myc-Par-4,
which coded a myc-tagged Par-4, Rt–PCR ampliﬁcation
was performed with another pair of primers, from which
the stop codon of Par-4 was removed. pcDNA3.1-myc-
Par-4 was similarly constructed, which encoded a myc
fusion protein containing a Par-4 deletion mutant, the
latter lacking 70 amino acids at the COOH terminus of
Par-4. Transfections were performed using the
Lipofectamine 2000 procedure following the manufac-
turer’s protocol. Green ﬂuorescent protein phMGFP
vector was cotransfected to determine transfection eﬃ-
ciency with ﬂow cytometry assay.
Northern blotting analysis
Samples of total RNA (10mg) were separated by electro-
phoresis through denaturing 1.2% agarose gels containing
1% formaldehyde and transferred onto nylon or nitrocel-
lulose membranes using standard molecular biological
techniques.ProbeswerederivedfromPCRproductsampli-
ﬁed with gene-speciﬁc primers for human Smac cDNA and
labeled with [a-
32P]dCTP using the Prime-It random prim-
ing kit (Stratagene, La Jolla, CA). Filters were reprobed
with the cDNA for GAPDH to correct for the amount of
RNA loaded onto the ﬁlters. Pre-hybridization and hybri-
dization were performed at 628C for 1h and overnight,
respectively. The blot was subjected to low and high strin-
gency washes using the buﬀers provided in the
NorthernMaxTM kit for Northern blots (Ambion Inc.,
Inc., Austin, TX). After hybridization, the membranes
were washed and exposed at  708C to X-ray ﬁlm using
an intensifying screen.
Immunoprecipitations
Cells were lysed in icecold immunoprecipitation buﬀer
(20mM Tris–Cl (pH 7.5), 150mM NaCl, 10% glycerol,
0.2% Nonidet P-40, and a protease inhibitor mixture
(Roche Applied Science, Indianapolis, IN, USA). Lysis
with immunoprecipitation buﬀer was complemented with
sonication (5 pulses) on ice. The lysate was cleared of cell
debris by centrifugation at 16000g at 48C for 30min. The
supernatant was saved for immunoprecipitation using
anti-Par-4 or anti-E2F1 conjugated to Sepharose beads
overnight at 48C with gentle agitation. The beads were
washed 3 times in lysis buﬀer, resuspended in
2 Laemmli buﬀer and boiled for 5min to release
bound proteins. Proteins were analysed by SDS–PAGE
and immunoblotting after transfer to polyvinylidene
diﬂuoride membranes.
Isolationof nuclear proteins binding tobiotinylated probes
Nuclear proteins binding to biotinylated probes were iso-
lated as described previously (28). Brieﬂy, oligonucleotides
representing E2F1-binding site on Smac promoter
sequence were synthesized, and 5mg of the sense strand
was 30-labelled using the terminal deoxynucleotidyltrans-
ferase and biotin-14-dATP. The biotin-labelled sense
strand was annealed to its complementary antisense
strand and puriﬁed over a Sephadex column. The concen-
tration of puriﬁed oligonucleotide was measured by absor-
bance at 260nm, and equal amounts of annealed
oligonucleotide were incubated with streptavidin-coated
magnetic beads (Promega) for 30min at room tempera-
ture. Coupling of the oligonucleotides to the beads was
measured by absorbance. For the binding reaction, 50mg
of nuclear extract alone or preincubated with anti-Par-4
antibody (R334) was used. The beads were captured by a
magnet, washed three times with a high salt buﬀer, and
resuspended in Laemmli buﬀer. The samples were heated
at 958C for 5min to elute all the proteins, loaded onto a
12% SDS–PAGE, electrophoresed, and transferred to a
nitrocellulose membrane. Par-4 and E2F1 were detected
using the Par-4 antibody (R334) or E2F1 antibody by
immunoblotting.
Nuclear extractpreparation and electrophoretic
mobility shiftassays (EMSA)
The double-stranded oligonucleotides used for EMSA of
E2F1-binding sites in Smac promoter are shown as fol-
lows: E2F1-binding BS3 site (underlined), 50-GCCCC
GCGCGGAAGTT-30; mutated E2F1-binding BS3 site
(underlined and in boldface), 50-GCCCCGCTTAGAA
GTT-30; E2F1-binding BS2 site (underlined), 50-GCG
CAGCGCGATGCCGG-30. The oligonucleotides were
50-end-labeled with [g-
32P]dATP. Nuclear proteins were
extracted using a Nuclear Protein Extraction Kit.
Electrophoretic mobility shift assay was performed by
using a Gel Shift Assay Kit following the manufacturer’s
instructions. The nuclear extracts containing 30mg of total
proteins were preincubated with gel shift binding buﬀer
for 10min, followed by the addition of 1mlo fa[ g-
32P]-
labelled, double-stranded oligonucleotide probe of E2F1
and incubation for 1h. Formed nuclear protein–DNA
complexes were dissolved in 4% nondenaturing polyacryl-
amide gels, and electrophoresis was performed under 90V
for 2h. Gels were dried and exposed to Kodak Biomax
ﬁlms at  708C for 48h. To assess the speciﬁcity of the
reaction, competition assays were performed with 100-
fold excess of unlabeled consensus oligonucleotide pairs
of E2F1. The unlabelled probes were added to binding
reaction mixture 10min before the addition of the labelled
probes. For the blocking reaction, 500ng each of anti-
Par-4 antibody (R334) and anti-E2F1 antibody were used.
Chromatin immunoprecipitation
hBMSCs cultured in the presence or absence of 100mMo f
glutamate for 24h were subjected to chromatin immuno-
precipitation. Chromatin immunoprecipitation was done
as described earlier (28). Cells were plated in a 100-mm
dish. About 70% conﬂuent dishes were treated with form-
aldehyde (1%) for 10min at 378C to cross-link proteins
to DNA. The cells were washed twice with PBS, pH 7.4,
containing protease/inhibitor mixture (Roche Applied
Science) and then lysed with lysis buﬀer containing 1%
SDS. Sonication of cross-linked chromatin was performed
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so that chromatin fragments thus obtained ranged from
500 to 2000bp in size. Soluble chromatin was subjected to
overnight immunoprecipitation with either anti-E2F1
antibody or anti-Par-4 antibody. A portion of the chro-
matin solution was kept to check the amount of input
DNA in diﬀerent samples before immunoprecipitation.
Following immunoprecipitation and elution, the eluent
was heated to 658C for 6h to reverse the cross-link.
Phenol/chloroform extraction was performed, and the
supernatant was ethanol-precipitated. DNA thus obtained
was resuspended in 10mM Tris, 1mM EDTA, pH 8.0 and
subjected to PCR. Forward and reverse primers selected
for Smac promoter are as follows: sense primer, 50-TTC
CCTTCAAGCCCTGGCCCGAAC-30; antisense primer,
50-ACGCCCCCACCCAAGGAAGCAGTC-30; PCR
products were resolved on a 1.5% agarose gel and stained
with ethidium bromide.
Luciferase assays
pGL3-Smac-P-Luc reporter was constructed as described
previously (28). Brieﬂy, the Smac promoter fragment
( 600 to  100bp), which contained E2F1-binding BS3
site, was cloned into the Xho I/Hind III site of pGL3-
Basic plasmid with the primer pairs indicated below.
Sense, 50-CCGCTCGAGCCGTCCGCCCCTCTGGGAC
GGCGC-30; Antisense, 50-CGCAAGCTTAGCAGTCGG
GATTGGGCAGGC-30. hBMSCs were transiently
cotransfected with appropriate pGL3-Smac-P-Luc reporter
plasmids (200ng) and either pcDNA3.1-myc-Par-4 or
pcDNA3.1-myc-Par-4 (200ng) using Lipofectamine
2000. In each transfection, cells were also cotransfected
with Renilla luciferase reporter plasmid pRL-CMV, which
served as an internal control for transfection eﬃciency.
Cell extracts were assayed for ﬁreﬂy and Renilla luciferase
activity. Fold-activation values were measured relative to
the levels of luciferase activity in cells transfected with
empty vectors and normalized by Renilla luciferase
activities.
RESULTS
Par-4played animportant role in glutamate-induced
hBMSCs apoptosis
We investigated whether glutamate could induce apopto-
sis in hBMSCs. The cells were exposed continuously to
1–100mM glutamate with diﬀerent time lengths. Upon
FACS analysis, we found that glutamate induced a dose-
dependent apoptosis in hBMSCs, which started at 1mM
and peaked at 100mM (Figure 1A), and glutamate
at 100mM induced a time-dependent cells apoptosis start-
ing at 6h and culminating at 24h (Figure 1A and
Supplementary Figure S1), which was conﬁrmed by
the following DNA laddering assay. As shown in
Figure 1B, after exposure to 100mM glutamate for 24h,
nucleosomal DNA fragmentation, an end stage apoptotic
event, was observed in hBMSCs. By contrast, no
DNA laddering was found in the cells without treatment
of glutamate. These data showed that glutamate could
induce apoptosis in hBMSCs.
To examine whether Par-4 was involved in the regula-
tion of glutamate-induced apoptosis in hBMSCs, Western
blotting was performed to detect Par-4 expression in the
cells treated with or without glutamate. Because the pro-
apoptotic function of Par-4 was attributed to its nuclear
translocation (13), Western blotting was performed with
nuclear extracts. As shown in Figure 1C, glutamate
induced a dose-dependent increase of Par-4 expression
in hBMSCs as compared with control.
To further conﬁrm the role of Par-4 in glutamate-
induced apoptosis, we studied the eﬀect of reducing
Par-4 expression on apoptosis of hBMSCs after treatment
with glutamate. hBMSCs was transfected with either
Par-4 speciﬁc siRNA, scrambled siRNA, or no siRNA
(Mock). The mRNA expression levels of Par-4 in trans-
ected cells were assessed by real time quantitative PCR
analysis. As shown in Figure 1D and Supplementary
Figure S2, Par-4-siRNA-1, one of the tested siRNA,
caused an eﬀective reduction of Par-4 mRNA. In all,
93% of Par-4 mRNA was suppressed by Par-4-siRNA-1.
Then, the transfected hBMSCs were treated with or with-
out equal concentration of glutamate (100mM) for 24h.
FACS analysis showed that the suppression of Par-4
expression signiﬁcantly attenuated the glutamate–induced
apoptosis (Figure 1E and Supplementary Figure S3).
By contrast, transient overexpression of Par-4 increased
the apoptosis cells in glutamate-treated hBMSCs
(Figure 1F). Together, these data indicated that Par-4
played an important role in glutamate-induced hBMSCs
apoptosis.
Ectopic expression ofPar-4 enhanced theexpression
ofSmac,which could be abrogatedby blocking
endogenousE2F1
To determine whether Smac is involved in glutamate-
induced hBMSCs apoptosis, Western blotting was per-
formed to detect the release of Smac from mitochondria.
Figure 2A showed that Smac protein releasing from mito-
chondria exhibited an apparent increase upon the treat-
ment with glutamate in a dose-dependent manner.
We next examined the relationship between Par-4
and Smac. hBMSCs were transfected with plasmid
pcDNA3.1-Par-4, which contained complete Par-4 CDS.
The same amount of empty pcDNA3 vector was
alsointroducedinto cellsas acontrol. Smacprotein expres-
sion was found to be upmodulated in the Par-4 overexpres-
sing hBMSCs (Figure 2B and Supplementary Figure S4).
Northernblotting showedthatSmactranscriptinhBMSCs
was enhanced as well (Figure 2C), suggesting a previously
undeﬁned transcriptional mechanism that Par-4 could
mediate upmodulation of Smac protein.
To characterize the involvement of E2F1 in the regula-
tion of Smac in hBMSCs, we blocked the expression of
endogenous E2F1 protein using siRNA. hBMSCs were
cotransfected with pcDNA3-Par-4 and plasmid pSiRNA-
E2F1-1, the latter speciﬁcally targeting E2F1 for gene
silencing. Western blotting analysis demonstrated Smac
expression was restrained following the inhibition of
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Figure S5). Real time quantitative RT–PCR showed that
pSiRNA-E2F1-1 could represse pcDNA3-Par-4-induced
increase of Smac mRNA transcription (Figure 2E). These
data indicated that E2F1 participated in Par-4-induced
Smac transcription and expression.
Par-4 andE2F1formed aproteincomplex in
glutamate-treated hBMSCs
Based on the strong correlation among Par-4, E2F1
and Smac from our above study, we further charac-
terized the interaction among these molecules. As shown
Figure 1. Par-4 plays an important role in glutamate-induced apoptosis of hBMSCs. (A) Glutamate induced apoptosis in hBMSCs. hBMSCs were
harvested after treatment with or without 1–100mM glutamate for 6, 12 or 24h. Cells were incubated with Annexin V-FITC and propidium
iodide and analysed by ﬂow cytometry. The percentages of apoptotic cells are presented in the bar graph. Results are means of triplicates and
representative for results of three independent experiments.  ,# ,, P<0.05. (B) DNA Fragmentation assay in apoptotic hBMSCs. hBMSCs were
harvested after treatment with (lane 1) or without (lane 2) 100mM glutamate for 24h. DNA were precipitated and electrophoresed in 1.5% agarose
gel. (C) Glutamate induced an increase of Par-4 expression in hBMSCs in a dose-dependent manner. Western blotting analysis was used to determine
Par-4 expression in nuclear extracts in hBMSCs exposed to various doses of glutamate. Intensity of Par-4 band from Western blotting
were quantiﬁed and normalized with Lamin A/C.  P<0.05, compared to the hBMSCs without treatment of glutamate. (D) Real time
Quantitative PCR assays for inhibitory eﬀect of siRNA targeting Par-4 gene. hBMSCs were transfected with either Par-4 siRNA-1,2,3,4, scrambled
siRNA or mock. Empty vector was transfected as a control. After 48h of transfection, relative amounts of Par-4 mRNA were measured by real-time
quantitative RT–PCR and normalized against GAPDH. Bars depict the percentage of Par-4 mRNA versus control.  P<0.05, versus control. (E)
Reduced Par-4 expression by siRNA inhibited glutamate-induced apoptosis of hBMSCs. hBMSCs were transfected with either Par-4-siRNA-1,
scrambled siRNA or mock. After 48h of transfection, hBMSCs were harvested in the presence or absence of 100mM glutamate for 24h.
The percentages of apoptosis in the cells were analysed by ﬂow cytometry. The result is presented in the bar graph. Values are mean SE
of ﬁve independent experiments.  P<0.05, compared to the cells with transfection of empty vector but without exposure of glutamate.
#P<0.05,
compared to the cells with transfection of empty vector and with exposure of glutamate. (F) Overexpression of Par-4 predisposed hBMSCs
to undergo apoptosis induced by glutamate. hBMSCs were transfected with either pcDNA3.1-Par-4 or empty vector pcDNA3.1. After 48h of
transfection, hBMSCs were exposed to 100mM glutamate for 24h. The percentages of apoptosis in the cells were analysed by ﬂow cytometry.
 P<0.05, compared to the cells with transfection of empty pcDNA3.1 but without exposure of glutamate.
#P<0.05, compared to the cells with
transfection of empty pcDNA3.1 and with exposure of glutamate.
5026 Nucleic Acids Research, 2008, Vol. 36, No. 15Figure 2. Ectopic expression of Par-4 enhanced Smac protein and transcript. Blocking endogenous E2F1 abrogated the enhancement of Par-4-
induced Smac expression. (A) Glutamate induced a release of Smac from mitochondria. hBMSCs were treated with glutamate at the dose from 1 to
100mM. Subcellular localization of Smac was determined by western blotting after 24h, and protein levels were quantiﬁed by computer-assisted
densitometry. Tubulin levels were analysed to conﬁrm equal protein loading in cytosol. Hsp60 was used to monitor the absence of mitochondrial
contamination in the cytosolic fraction and to verify equal protein loading in mitochondrial fraction. Intensities of bands from western blotting
analysis were quantiﬁed. Results are indicated as the ratio between Smac levels in mitochondria versus Smac levels in cytosol and are mean S.E. of
three independent experiments performed in duplicate.  P<0.05 versus the cells without treatment of glutamate. (B) Overexpression of Par-4
enhanced Smac protein in hBMSCs. hBMSCs were transfected with either pcDNA3.1-Par-4 or empty pcDNA3.1 vector. Subcellular localization
of Smac was determined by Western blotting after 48h, and protein levels were quantiﬁed by computer-assisted densitometry. Tubulin levels were
analysed to conﬁrm equal protein loading in cytosol. Hsp60 was used to monitor the absence of mitochondrial contamination in the cytosolic
fraction and to verify equal protein loading in mitochondrial fraction. Results are indicated as the ratio between Smac levels in mitochondria versus
Smac levels in cytosol and are the mean SE of three independent experiments performed in duplicate.  P<0.05 versus the cells transfected with
empty vector. (C) Overexpression of Par-4 enhanced Smac transcript in hBMSCs. Northern blotting was used to determine Smac mRNA in
hBMSCs. hBMSCs were transfected with either pcDNA3.1-Par-4 or empty pcDNA3.1 vector. After 24h of transfection, total cellular RNAs
were separated and hybridized to 32P-labelled DNA probes. GAPDH probe was used to normalize for diﬀerences in RNA loading. Intensities of
bands from northern blotting analysis were quantitated and normalized with GAPDH. Arbitrary unit=(ASmac/AGAPDH) 100%. Values are
mean SE of three independent experiments performed in duplicate.  P<0.05 versus the cells transfected with empty vector. (D) Blocking endo-
genous E2F1 by siRNA abrogated the enhancement of Par-4-induced Smac protein in hBMSCs. hBMSCs were co-transfected with pcDNA3.1-Par-4
and psiSTRIKE-E2F1-siRNA-1 vector. As controls, these plasmids or empty vectors were respectively transfected into hBMSCs. Subcellular
localization of Smac/DIABLO was determined by western blotting after 48h, and protein levels were quantiﬁed by computer-assisted densitometry.
Tubulin protein was analysed to conﬁrm equal protein loading in cytosol. Hsp60 was used to monitor the absence of mitochondrial contamination in
the cytosolic fraction and to verify equal protein loading in mitochondrial fraction. Intensities of bands from western blotting analysis were
quantitated. Results are indicated as the ratio between Smac levels in mitochondria versus Smac levels in cytosol and are the mean S.E. of
three independent experiments performed in duplicate.  P<0.05 versus untransfected cells (the ﬁrst bar at left).  P<0.05 versus hBMSCs transfected
only with pcDNA3.1-Par-4. (E) Blocking endogenous E2F1 by siRNA abrogated enhancement of Par-4-induced Smac transcript in hBMSCs.
hBMSCs were co-transfected with pcDNA3.1-Par-4 and psiSTRIKE-E2F1-siRNA-1 vector. As a control, empty vector was respectively transfected
into hBMSCs. After 24h of transfection, relative amount of Par-4 mRNA was measured by real-time quantitative RT–PCR and normalized against
GAPDH. Bars depict the percentage of Par-4 mRNA versus that of untransfected cells. Values are mean SE of three independent experiments.
 P<0.05 versus untransfected cells (control, the ﬁrst bar at left).
#P<0.05 versus transfected cells only with pcDNA3.1-Par-4.
Nucleic Acids Research, 2008, Vol. 36, No. 15 5027in Figure 3, Par-4 co-immunoprecipitated with E2F1
protein in nuclear extracts from the glutamate-
treated hBMSCs, indicating the direct interaction
between Par-4 and E2F1. By contrast, in nuclear extracts
from the hBMSCs without the treatment of glutamate,
Par-4 failed to associate with E2F1. These data suggested
that glutamate induced the formation of protein complex
containing Par-4 and E2F1.
Itwas E2F1, notPar-4, which directly boundto Smac
promoter inPar-4-E2F1 complex, andPar-4 exerted its
transcriptional controlon Smac gene throughindirect
interacting withE2F1
Next, we used a previously identiﬁed E2F1-binding site
BS3 ( 200 to  193bp relative to ATG) on the Smac pro-
moter as bait to pull out potential interacting molecules
(12). This Smac promoter sequence was labelled with
biotin using terminal deoxynucleotidyltransferase and
incubated with nuclear extracts from hBMSCs treated
with or without 100mM glutamate for 24h. Following
this, the samples were subjected to high salt washes to
remove any non-speciﬁc binding. The washed complex
was pulled out, using streptavidin conjugated to magnetic
beads, with the help of a magnet. The proteins binding to
the promoter were eluted by boiling in Laemmli’s buﬀer
and subjected to SDS–PAGE, and Western blotting for
Par-4 was performed using anti-Par-4 antibody. Indeed,
we found that Par-4 and E2F1 existed in nuclear extracts
from glutamate-treated cells (Figure 4A, lane 1; Figure 4B,
lane 1). The Par-4-speciﬁc antibody (R334) has been
shown previously (28) to disrupt the interaction between
Par-4 and other molecules. We could not almost detect
Par-4 in the nuclear extracts preincubated with the R334
antibody and then incubated with the biotin-labeled
E2F1-binding site on Smac promoter (Figure 4A,
lane 2). Similarly, E2F1 also decreased markedly upon
the pre-incubation of the neutralizing antibody against
E2F1 (Figure 4B, lane 2). Together, this set of experiments
indicated that Par-4 and E2F1 bound either indirectly or
directly to Smac promoter in glutamate-treated hBMSCs.
To further elucidate the molecular mechanisms
by which Par-4 and E2F1 interact with the Smac pro-
moter, EMSA experiments in vitro were performed
with the nuclear extracts from hBMSCs treated with glu-
tamate. Previously deﬁned E2F1-binding site BS3 ( 200
to  193bp relative to ATG) on Smac promoter were used
as probes (12). Two complexes were formed with the BS3
oligonucleotide (Figure 4C, lane 2). Competition with
increasing amounts of cold competitor demonstrated
that both complexes were speciﬁc (Figure 4C, lane 3).
To determine the presence of Par-4 and E2F1 in the com-
plexes formed, nuclear extracts from the glutamate-treated
hBMSCs were incubated with the BS3 probe along with
antibodies directed against Par-4 or E2F1. The anti-Par-4
antibody is directed against the COOH terminus of Par-4
and has been demonstrated previously as a blocking anti-
body (28). The anti-Par-4 antibody caused disappearance
of the slower migrating complex, indicating the presence
of Par-4 (Figure 4C, lane 4). The neutralizing antibody
against E2F1 caused disappearance of both the faster
and the slower migrating complex, thus indicating the pre-
sence of E2F1 in both the complexes (Figure 4C, lane 5).
These results supported that it was E2F1, not Par-4,i n
Par-4-E2F1 proteins complex that directly bound to Smac
promoter, and that Par-4 might indirectly exert its tran-
scriptional control on Smac gene though interacting with
E2F1. The BS3 E2F1-binding site was also used as a probe
to perform EMSA with nuclear extracts from the
hBMSCs without treatment of glutamate. However, no
DNA–protein complex was found (Figure 4C, lane 7).
Therefore, the presence of glutamate was critical for the
formation of these DNA–protein complexes.
Par-4-E2F1 complex boundto theBS3 Site
( 200 to 193bp relative toATG) within Smac
promoter in glutamate-treated hBMSCs invivo
To evaluate directly the potential signiﬁcance of physical
interactions among Par-4, E2F1 and Smac promoter,
we investigated whether Par-4 and E2F1 associate on
the chromatin of endogenous Smac promoter using the
chromatin immunoprecipitation assay. We immunopreci-
pitated chromatin from the glutamate-treated hBMSCs,
using speciﬁc antibodies against Par-4 and E2F1 or no
Figure 2. Continued.
Figure 3. Glutamate induced the formation of protein complex contain-
ing Par-4 and E2F1. Immunoprecipitations and western blotting ana-
lysis were performed with whole-cell extracts in hBMSCs with or
without treatment of 100mM glutamate for 24h. The whole-cell
extracts (0.15mg protein/0.5ml), were mixed with 10ml of anti-Par-4
antibody or preimmune serum. The mixtures were incubated at 48C for
1h, and then 10ml protein A Sepharose beads were added. The mix-
tures were incubated for 1h and, after being washed, the beads were
submitted for western blotting analysis with anti-E2F1 antibody.
Immunoprecipitations with E2F1 antibody and Western blotting with
Par-4 antibody were similarly performed. The other E2F1 family mem-
bers were used as control.
5028 Nucleic Acids Research, 2008, Vol. 36, No. 15antibody at all as a control. Genomic DNA fragments
bound to Par-4 or E2F1 were analysed by PCR using
primers upstream of the BS3 ( 200 to  193bp relative
to ATG) site within Smac promoter. Analysis of genomic
DNA immunoprecipitated with anti-Par-4 antibody
revealed Smac promoter in glutamate-treated hBMSCs
(Figure 5, lane 4). Also, immunoprecipitates from anti-
E2F1 antibody revealed the presence of Smac promoter
(Figure 5, lane 5). As expected, when minus the antibodies
in the immunoprecipitation procedure, no genomic DNA
was pulled out (Figure 5, lane 6). Chromatin immunopre-
cipitated with anti-Par-4 antibody or anti-E2F1 antibody
was subjected to PCR using primers representing BS2
( 542 to  535bp relative to ATG) site, another pre-
viously reported E2F1-binding site. No DNA could be
ampliﬁed from the chromatins, (data not shown), demon-
strating that Par-4 and E2F1 speciﬁcally bind to the BS3
( 200 to  193bp relative to ATG) site on the Smac pro-
moter. In addition, we did not observe any Smac promoter
pulled down by anti-Par-4 or anti-E2F1 antibody in
hBMSCs without exposure to glutamate. Together, these
ﬁndings strongly support the idea that Par-4 and E2F1
interact with a previously deﬁned BS3 site within Smac
promoter in vivo in glutamate-treated hBMSCs.
The indirect transcriptional regulation of Par-4on Smac
was dependanton its COOH terminus-mediated
interaction between Par-4 andE2F1 inhBMSCs
To identify structural determinants of Par-4 responsible
for its regulatory function on Smac transcription, we
focused on investigating the role of the COOH terminus
of Par-4, since a stretch of 70 amino acids at this region
showed homology to a domain referred to as the death
domain, which was also found in other pro-apoptotic pro-
teins such as Fas, FADD and TNFR-1 (6,20). We engi-
neered and constructed plasmids pcDNA3.1-myc-Par-4
and pcDN3.1-myc-Par-4, encoding a myc fusion protein
Figure 4. Par-4 and E2F1 bound to Smac promoter in hBMSCs with
exposure of glutamate. (A and B) hBMSCs were treated with or with-
out 100mM glutamate for 24h. And nuclear proteins were isolated.
Before the binding reaction, 50mg of nuclear extract was preincubated
with either anti-Par-4 antibody (R334) or anti-E2F1 antibody.
Subsequently, these nuclear extracts were co-incubated with the mag-
netic beads containing biotinylated oligonucleotide sequence of SB3
sites within Smac promoter for binding reaction. The beads were cap-
tured by a magnet, washed three times with a high salt buﬀer, and
resuspended in Laemmli buﬀer. The samples were heated at 958C for
5min to elute all the proteins, loaded onto a 12% SDS–PAGE, elec-
trophoresed, and transferred to a nitrocellulose membrane. Par-4 and
E2F1 were detected using the Par-4 antibody (R334) or E2F1 antibody
by immunoblotting. (C) DNA-binding activity of E2F1-binding sites
BS3 ( 200 to  193bp) within Smac promoter was assessed by electro-
phoretic mobility shift assay. After treatment with or without 100mM
glutamate for 24h, nuclear extracts were obtained from the hBMSCs.
Nuclear extracts were incubated with the probes in the presence or
absence of antibodies directed against Par-4 or E2F1. In competition
studies, a 100-fold molar excess of unlabelled oligonucleotide was
added to binding reaction mixture before the addition of the labelled
probes. Results shown are representative of three independent
experiments.
Figure 5. Demonstration of in vivo binding of Par-4 and E2F1 to BS3
site ( 200 to  193bp relative to ATG) on the Smac/DIABLO pro-
moter by chromatin immunoprecipitation. hBMSCs were treated with
or without 100mM glutamate for 24h. Chromatin lysates were immu-
noprecipitated (IP) with either antibody against Par-4 or antibody
against E2F1. The samples were processed as described under
‘Materials and Methods’ section. Immunoprecipitated DNA was ampli-
ﬁed using primers representing the BS3 site ( 200 to 193bp relative to
ATG) on Smac promoter. PCR analysis of the total input DNA was
also preformed. Products of chromatin immunoprecipitation and PCR
ampliﬁcation were analysed by 2% agarose gel electrophoresis and
beta-actin was performed as a negative control. Results are representa-
tive of three independent experiments.
Nucleic Acids Research, 2008, Vol. 36, No. 15 5029containing full-length Par-4 protein or a deletion mutant,
respectively, of which the latter lacked 70 amino acids
at the COOH terminus. Then, pGL3-Smac-P-Luc
reporter, which contained Smac promoter fragment
( 600 to  100bp relative to ATG), was cotransfected
into hBMSCs with pcDNA3.1-myc-Par-4 or pcDNA3.1-
myc-Par-4. Equal concentrations of Renilla reporter
plasmid pRL-CMV were also co-introduced into cells as
an internal control. Luciferase activities were measured
and pGL3-Smac-P-Luc reporter activities normalized to
pRL-CMV internal standard were presented in the histo-
gram with arbitrary units. As shown in Figure 6A,
cotransfection with increasing amounts of full-length
Par-4 resulted in an increased activity of Smac promoter
in a dose-dependent manner, whereas mutant Par-4 or
empty vector failed to give rise to noticeable activation
of Smac promoter. These data indicated the COOH ter-
minus of Par-4 was essential for Par-4-mediated activa-
tion of Smac promoter.
Although, as delineated previously (15), no evidence
was provided that Par-4 could directly bind to DNA
molecule, our above studies has demonstrated that Par-4
and E2F1 could form protein complex and bind to Smac
promoter. Hence, we could set up a hypothesis that the
COOH terminus of Par-4 might contribute to proteins
complex formation of Par-4 and E2F1, and then via
recruitment of E2F1 to Smac promoter, Par-4 induced
indirectly Smac transcription. In order to further corrobo-
rate this hypothesis, we performed the co-immunoprecipi-
tation assays for measuring the interaction between Par-4
and E2F1. As shown in Figure 6B (lane 2), from nuclear
extracts of the cells transfected with pcDNA3.1-myc-Par-4
and following treated with glutamate, myc-Par-4 was
immunoprecipitated using anti-myc antibody, and asso-
ciated E2F1 were detected by immunoblotting. However,
Par-4 deletion mutant, which lacked the COOH terminus
of wild-type Par-4 protein, failed to associate with E2F1
(Figure 6B, lane 5). The ﬁndings validated the essentiality
of the COOH terminus of Par-4 for Par-4-E2F1 complex
formation. Taken together, we concluded that the COOH
terminus of Par-4, by which Par-4 associated with E2F1
and bound to Smac promoter, was functionally required
for Par-4-mediated activation of Smac promoter in
hBMSCs.
DISCUSSION
In this study, we report for the ﬁrst time that glutamate
can induce apoptosis in hBMSCs by a mechanism involv-
ing pro-apoptotic gene Par-4. Glutamate-induced neuro-
toxicity is an important contributor in acute neuronal
damages and in chronic neurodegenerative diseases
(16,17). Therefore, implanted stem cells will be sure to
suﬀer from glutamate-mediated injury. We observed that
glutamate induced a dose- and time-dependent apoptosis
in hBMSCs, which was consistent with previous studies
carried out in neural cells (4,16–18). As a pro-apoptotic
factor, Par-4 is initially identiﬁed as a product of gene
upregulated in prostate tumour cells undergoing apoptosis
(5). Recently, growing evidence show that increased
expression of Par-4 also regulates neuronal apoptosis,
especially when exposed to metabolic insults such as glu-
tamate and intracellular calcium elevation (15,19). In the
current study, we demonstrated that the suppression of
Par-4 expression greatly attenuated apoptosis in gluta-
mate-treated hBMSCs, whereas Par-4 overexpression
increased the percentage of apoptotic cells, implying
that Par-4 played a critical role in glutamate-induced
hBMSCs apoptosis.
Previously, several signal pathways, including WT1/
Bcl-2, Fas/Fas ligand, PKC/p38 mitogen-activated protein
kinase (MAPK), Ras/NF-kB, DAP-like or ZIP kinase
Figure 6. The indirectly regulation of Par-4 on Smac/DIABLO promo-
ter was dependant on its COOH terminus-mediated interaction between
Par-4 and E2F1 in the hBMSCs. (A) Luciferase activity assays.
hBMSCs were co-transfected with pGL3-Smac-P-Luc reporter and
pRL-CMV vector as an internal control for transfection eﬃciency. At
the same time the cells were also transfected with either increasing
amounts of pcDNA3.1-myc-Par-4 or pcDNA3.1-myc-Par-4,o ra n
empty pcDNA3.1 vector. Luciferase activity was determined at 24h
after transfection. Non-transfected cells were used as the background.
All values were normalized for expression of Renilla luciferase and
expressed as X-fold induction relative to the activity of pGL3-Smac-
P-Luc reporter co-transfected with empty pcDNA3.1. Shown is a repre-
sentative experiment of three independent experiments. Values are
mean SE of three independent experiments.  P<0.05 versus cells
co-transfected with pGL3-Smac-P-Luc reporter and empty
pcDNA3.1. (B) Immunoprecipitations and Western blotting analysis
of nuclear extracts in hBMSCs. Cells was transfected with
pcDNA3.1-myc-Par-4 or pcDNA3.1-myc-Par-4. After 24h of trans-
fection, nuclear proteins were extracted. Then the nuclear extracts,
(0.15mg protein/0.5ml), were mixed with 10ml of anti-myc antibody
or pre-immune serum. The mixtures were incubated at 48C for 1h, and
then 10ml protein A Sepharose beads were added. The mixtures were
incubated for 1h and, after being washed, the beads were submitted for
western blotting analysis with anti-E2F1 antibody. Lanes 1 and 4,
protein A gel only; lanes 2 and 5, cell lysate immunoprecipitated with
anti-myc antibody; lanes 3 and 6, cell lysate incubated with pre-immune
serum.
5030 Nucleic Acids Research, 2008, Vol. 36, No. 15(DIK/ZIP kinase), extracellular signal regulated-kinase
(ERK), have been demonstrated to be involved in Par-4-
mediated apoptosis (6,9,20,21). Our studies showed that
Par-4 ectopic expression in hBMSCs resulted in increased
release of Smac protein from mitochondria and elevation
of Smac message RNA, suggesting a previously undeﬁned
transcriptional mechanism for Par-4-mediated Smac
upmodulation. However, previous studies did not provide
any evidence to support the direct interaction between
Par-4 protein and Smac promoter. Our data showed
that blocking endogenous E2F1 decreased Par-4-induced
Smac transcription, indicating that both Par-4 and E2F1
were required for Smac transcription regulation.
Numerous studies showed that ectopic expression of
E2F1 induced apoptosis by diﬀerent mechanisms.
Apoptosis-related E2F1 target genes, such as p73, Apaf1,
noxa, bim and akt, are involved in both p53-dependent
and p53-independent apoptotic regulation (22–27).
A recent study demonstrated that enhanced accumulation
of nuclear E2F1 upregulated Smac expression and subse-
quently accelerated mitochondria-mediated apoptosis,
implying that Smac was an E2F1 target gene (12). In
agreement with the study, our data showed that the
increased expression of Smac gene in glutamate-treated
hBMSCs were E2F1-dependent, at least partially.
We further conﬁrmed that both Par-4 and E2F1 pro-
teins participated in the formation of a complex that
bound to the BS3 site ( 200 to  193bp relative to
ATG) on Smac promoter, which was previously identiﬁed
as a site where E2F1 bound to and increased transcription
of Smac gene in human H1299 non-small lung carcinoma
cells (12). Our results indicated that this site was also
employed to drive the transcription of Smac in
hBMSCs. Similar mechanism of Par-4 mediated indirect
transcriptional regulation was delineated by Sangeeta and
colleagues as well. They demonstrated that Par-4 asso-
ciated with WT1 and bound to the bcl-2 promoter to
transcriptionally regulate Bcl-2 expression in an andro-
gen-independent prostate cancer cell line (28). In particu-
lar, our results suggested that it was E2F1, not Par-4, that
directly bound to Smac promoter in the DNA–proteins
complex, which implied that Par-4, indirectly, exert its
transcriptional control on Smac gene though interacting
with E2F1.
Consistent with previous studies (6,20), our study vali-
dated the functional signiﬁcance of the COOH terminus of
Par-4 protein in hBMSCs apoptosis. The COOH terminus
of Par-4 protein containing a leucine zipper domain has
been shown to be essential in Par-4 binding to PKC, WT1,
ZIPK/Daxx and THAP, and their interactions promoted
cell apoptosis (6,20,29). Here we showed that the mutant
of Par-4, which lacked 70 amino acids at the COOH ter-
minus, failed to co-immunoprecipitate with E2F1 protein,
implying that this region was also required for the inter-
action between Par-4 and E2F1. With luciferase activity
analysis, we found that the increased expression of Par-4
resulted in an increased activity of Smac promoter in a
dose-dependent manner, whereas Par-4 mutant failed to
active Smac promoter. Therefore, we further corroborated
that the indirect transcripional regulation of Par-4 on
Smac was depended on its COOH terminus-mediated
interaction between Par-4 and E2F1.
Recently, it was reported that the COOH terminus of or
possibly the full-length Par-4 protein was not required for
apoptosis in primary ﬁbroblasts (30). This discrepancy
may be due to the diﬀerent cell types, since in the same
experiment settings, depletion of Par-4 in HeLa cells
conferred a signiﬁcant resistant to various apoptotic
agents (30).
In summary, we show that the proteins–DNA complex,
containing Par-4 protein, E2F1 protein and Smac promo-
ter, contributes to glutamate-induced apoptosis in
hBMSCs. The Par-4 mediated indirect transcripional
regulation on Smac gene depended on its COOH termi-
nus-mediated interaction between Par-4 and E2F1. Our
studies provide a further understanding of molecular
mechanism in glutamate induced hBMSCs apoptosis,
which beneﬁt stem-cell therapy in ischemic brain damage.
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